MAPT and frontotemporal dementia: As a biomarker of tau protein pathology in Alzheimer's disease and frontotemporal dementia, increased expression of glyoxalase I was reported in mouse models and patients, and tau aggregation was observed as an effect of elevated MG levels [53-55].